Down 7.3% on a down day: the S&P 500 is down 4.4% and 9 in 10 stocks are lower; health care stocks are down 5.2%; fertilizer stocks and telecom stocks rose.
Fell on Oct 29
Down 8% on Oct 29 while the S&P 500 fell 0.4%.
NVCR's Quality Score fell 1 point on Thu, Nov 5, to -3.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its 2023 high | Down 88% |
| Latest filing | 8-K, Oct 29 |
TodayOn a down day.
After its last 4 reports it closed +10.0% on average, higher 2 of 4 times.
Poorfor quality, not price, 0 of 14 chart checks firingWhat the Quality Score means
NVCR is #77 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 77 |
Expected to report Thu Feb 25, before the open (in 112 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $193.4M; a loss of $0.09 a share.
“This increase was primarily driven by 19% global active patient growth.”
NVCR's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Total net revenue | $736M to $743M |
“This improvement was primarily driven by higher net revenue primarily attributable to higher active patient volumes in conjunction with lower cost of revenues per active patient, driven primarily by improved array utilization and manufacturing efficiencies.”
From its results filing (SEC filing · Oct 29)
Sales grew 5.8% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 0.5% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 29, 2026 | -11.0% | -7.5% | +3.1% |
| Jul 23, 2026 | +15.6% | +28.4% | -2.4% |
| Apr 30, 2026 | +12.0% | +27.5% | +38.3% |
Sales grew in six of the last seven years, to $655M in 2025. It made a profit in one of the eight years.
9 insiders sold $948K across 9 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: NVCR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
“The market for cancer treatments is intensely competitive, subject to rapid change and significantly affected by new product and treatment introductions and other activities of industry participants.”
NVCR scores -3 today, which Breakaway calls Poor. It is #77 of 85 in Medical Devices by Quality Score, with 0 of 14 chart checks firing. Down 8% on Oct 29 while the S&P 500 fell 0.4%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
NVCR scores -3 today, which Breakaway calls Poor (below zero). That is #77 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NVCR's -3.
9 insiders sold $948K across 9 filings in the last 6 months. No open-market buys on record. The newest is Michal Nath Puri, Chief Human Resources Officer, who sold $9K on Nov 2. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.